24/7 Pet Web Search

Search results

1. Results From The WOW.Com Content Network

2. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban. Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [6] [7] [8] Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a ...

3. Explainer-Why the US is negotiating the price of 10 drugs - AOL

   www.aol.com/news/explainer-why-us-negotiating...

   Medicare plans to send its first offers to manufacturers by Feb. 1. They will have 30 days to make counteroffers. The negotiations must end by Aug. 1, and Medicare will publish its list of new ...

4. Blood thinners, diabetes meds among first 10 drugs for US ...

   www.aol.com/news/us-names-first-10-drugs...

   Wells Fargo analyst Mohit Bansal said the savings from negotiations on Jardiance, Januvia, AstraZeneca's Farxiga and Novo's Insulin Aspart, which cost the agency about $16.5 billion total, could ...

5. Biden targets diabetes drug Jardiance, blood thinner Eliquis ...

   www.aol.com/finance/biden-targets-diabetes-drug...

   By February 2024, the government will make its first offer on a maximum fair price and then give drugmakers time to respond. Any negotiated prices won't take hold until 2026. More drugs could be ...

6. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Discovery and development of direct Xa inhibitors. Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States ...